Merit Medical Systems, Inc.  

(Public, NASDAQ:MMSI)   Watch this stock  
Find more results for MMSI
46.55
+1.05 (2.31%)
Real-time:   3:25PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.22 - 47.50
52 week 24.23 - 47.50
Open 45.50
Vol / Avg. 307,607.00/297,682.00
Mkt cap 2.34B
P/E 77.15
Div/yield     -
EPS 0.60
Shares 50.20M
Beta 1.23
Inst. own 92%
Feb 19, 2018
Q4 2017 Merit Medical Systems Inc Earnings Release (Estimated) - 12:00AM EST - Add to calendar
Nov 29, 2017
Merit Medical Systems Inc at Piper Jaffray Healthcare Conference
Nov 16, 2017
Merit Medical Systems Inc Signs Purchase Agreement with Becton Dickinson and Co for Divestment Assets Conference Call - Webcast
Nov 16, 2017
Merit Medical Systems Inc at Jefferies Global Healthcare Conference
Nov 9, 2017
Merit Medical Systems Inc at Canaccord Genuity Medical Technologies & Diagnostics Forum
Oct 25, 2017
Q3 2017 Merit Medical Systems Inc Earnings Call - Webcast
Oct 25, 2017
Q3 2017 Merit Medical Systems Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1.99% 3.33%
Operating margin 0.06% 5.78%
EBITD margin - 13.03%
Return on average assets -1.34% 2.34%
Return on average equity -2.15% 4.17%
Employees 4,150 -
CDP Score - -

Address

1600 W Merit Pkwy
SOUTH JORDAN, UT 84095-2416
United States - Map
+1-801-2531600 (Phone)
+1-801-2531652 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Merit Medical Systems, Inc. is a manufacturer and marketer of disposable medical devices used in a range of interventional, diagnostic and therapeutic medical procedures. The Company operates in two segments: cardiovascular and endoscopy. The cardiovascular segment consists of cardiology and radiology devices, which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases, and includes embolotherapeutic, cardiac rhythm management (CRM), electrophysiology (EP), and interventional oncology and spine devices. Its endoscopy segment consists of gastroenterology and pulmonology medical devices, which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Within its segments, the Company offers products focused in four product groups: peripheral intervention, cardiac intervention, interventional oncology and spine, and endoscopy.

Officers and directors

Fred P. Lampropoulos Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Bernard J. Birkett Chief Financial Officer, Treasurer
Age: 48
Bio & Compensation  - Reuters
Joseph C. Wright President - International Division
Age: 47
Bio & Compensation  - Reuters
Ronald A. Frost Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Justin J. Lampropoulos Executive Vice President - Sales, Marketing and Strategy
Age: 34
Bio & Compensation  - Reuters
Brian G. Lloyd Chief Legal Officer, Corporate Secretary
Age: 56
Bio & Compensation  - Reuters
Nolan E. Karras Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
David Ming-Teh Liu Director
Age: 43
Bio & Compensation  - Reuters
Kent W. Stanger Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
A. Scott Anderson Independent Director
Age: 70
Bio & Compensation  - Reuters